Post-operative Radiotherapy Omission in Selected Patients with Early Breast Cancer Trial International VErsion (PROSPECTIVE)

Not Applicable

Not yet recruiting

• Conditions: Breast Cancer Female; Breast Cancer

• Registration Number: NCT06445738
• Lead Sponsor: Breast Cancer Trials, Australia and New Zealand

Brief Summary

The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery.

The main question it aims to answer is:

\* Will cancer come back in the same breast as the original cancer in patients who have surgery for their breast cancer, but who don't have radiotherapy afterwards because the results of an MRI before surgery showed favourable characteristics for not having radiotherapy.

Detailed Description

Breast cancer is the most common serious malignancy in women and most patients are suitable for therapy involving surgery and adjuvant radiotherapy (RT). For most patients, there is a lack of evidence that breast conserving surgery without adjuvant RT is safe and therefore patients bear the costs, inconvenience and morbidity of RT. Prior attempts to identify large subsets of patients for whom RT can be safely omitted based on clinicopathological features of the index cancer have had limited success, and so RT is currently omitted only in some women over 65 or 70 with small low risk cancers. Identification of a much larger subset of patients in whom adjuvant RT could be safely omitted would be hugely significant, not only to the patients, but to the entire health system.

The ANZ 1002 PROSPECT study was a two-arm phase II study that used breast MRI findings and pathological features to identify a group of patients with low risk early breast cancer in whom RT may be safely omitted. The findings at the primary strongly support the hypothesis and suggest that the combination of preoperative MRI and pathological features can identify a substantial group of early breast cancer patients in whom adjuvant RT can be safely omitted.

A Health Economic analysis of PROSPECT found that the avoided costs of RT and its potential side effects is likely to substantially outweigh the extra cost of MRI scans and associated investigations. Parallel cross-sectional studies assessing Fear of Cancer Recurrence (FCR) and Health Related Quality of Life (HRQoL) in patients taking part in PROSPECT who either did or did not receive RT and a control group found a substantially lower FCR in PROSPECT patients who omitted RT as well as improved HRQoL.

The majority of screened and eligible patients (427/443 and 193/201, respectively) for PROSPECT were recruited from two Australian sites. Before the PROSPECT approach can be widely adopted, the findings need to be replicated in a multicentre, international study. In addition, patient reported outcomes and health economic assessments need to be performed prospectively and longitudinally.

PROSPECTIVE is the follow-up to PROSPECT which will address these issues, and also include translational research aspects to further study the natural history and outcomes of this group of lower risk early breast cancers.

Study Timeline

• Study First Submitted: 2024-05-24
• Study First Submitted QC: 2024-06-04
• Study First Posted: 2024-06-06
• Status Verified: 2024-11
• Last Update Submitted: 2025-02-03
• Last Update Posted: 2025-02-05
• Study Start: 2025-03
• Primary Completion: 2032-03
• Study Completion: 2039-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 1400

Inclusion Criteria

For inclusion in the study at Registration, participants must fulfil all of the following criteria:

1. Has provided written, informed consent to participate in the study.

2. Female participants ≥ 50 years old with histologically* confirmed ER-positive and/or HER2-positive invasive breast cancer.

3. In good health and suitable for prolonged follow up with a life expectancy of at least 10 years; willing to be followed up for 10 years.

4. Breast imaging indicating unifocal**, unilateral breast cancer must have been performed before pre-registration.

5. Willing/able to have surgery within 8 weeks of registration or pre-operative MRI, whichever occurs later.

6. Pathology material from index cancer must be available.

7. Have ECOG performance status 0-2.

8. Participants with Grade 3 cancer and/or HER2-positive cancer must agree to comply with systemic treatment recommendations.

   • Oestrogen receptor and progesterone receptor status of invasive cancer will be assessed by immunohistochemistry on the diagnostic core biopsy specimen. The IHC results will be reported as percentage of nuclei stained and a score of intensity from negative, weak, intermediate or high staining

     • HER2 neu status will be assessed by immunohistochemistry and will be scored as follows46:

       • 0 or 1+ (HER2 negative): No staining or membrane staining that is incomplete and is faint/barely perceptible and in ≤ 10% of tumour cells (0); or incomplete membrane staining that is faint/barely perceptible and in > 10% of tumour cells (1+).
       • 2+ (equivocal): weak to moderate complete membrane staining observed in > 10% of tumour cells. Must order reflex test (same specimen using ISH) or order a new test (new specimen if available using HIS or ISH).
       • 3+ (HER2 positive): Circumferential membrane staining that is complete, intense and in > 10% of tumour cells.

Exclusion Criteria

Any one of the following at Registration is regarded as a criterion for exclusion from the study:

1. Triple negative breast cancer (ER-negative and PR-negative and HER2-negative) where ER and PR positivity is defined as Any one of the following at Registration is regarded as a criterion for exclusion from the study:

1. Triple negative breast cancer (ER-negative and PR-negative and HER2-negative) where ER and PR positivity is defined as ≥ 10% staining on IHC47.
2. Previous ipsilateral in-situ or invasive breast cancer.
3. Participants who have a mastectomy for the index cancer.
4. Lymphovascular invasion.
5. Multifocal/multicentric breast cancer.
6. Distant metastasis at diagnosis.
7. Bilateral breast cancer.
8. Known breast cancer predisposition gene mutation carriers (BRCA 1 or 2, PALB2, CHEK2, ATM, CDK1, p53).
9. Contraindication to MRI scanning.
10. Concurrent illness/conditions which limits life expectancy to 10 years.
11. Inability to give informed consent. 10% staining on IHC47.

2. Previous ipsilateral in-situ or invasive breast cancer. 3) Participants who have a mastectomy for the index cancer. 4) Lymphovascular invasion. 5) Multifocal/multicentric breast cancer. 6) Distant metastasis at diagnosis. 7) Bilateral breast cancer. 8) Known breast cancer predisposition gene mutation carriers (BRCA 1 or 2, PALB2, CHEK2, ATM, CDK1, p53).

3. Contraindication to MRI scanning. 10) Concurrent illness/conditions which limits life expectancy to 10 years. 11) Inability to give informed consent.

Allocation: Arm A - Radiotherapy Omission

In addition to the above criteria, for inclusion in the omission of radiation therapy arm of the study after surgery, participants must fulfil all the following criteria (see Section 9.5.2). Participants not fulfilling any one of the following criterial will be allocated to Arm B:

1. Female participants ≥ 50 years old with histologically* confirmed ER-positive and/or HER2-positive, unifocal**, unilateral invasive breast cancer.

2. Has nil/minimal or mild parenchymal enhancement on pre-operative MRI.

3. Breast conserving surgery with invasive primary tumour (including any surrounding DCIS) ≤ 20 mm.

4. Radial resection margins must be ≥ 2 mm clear of any invasive cancer and ≥ 2 mm clear of any DCIS. Superficial or deep margins of < 2 mm for invasive cancer and DCIS are allowed if all breast tissue from the subcutaneous tissue or pectoralis fascia respectively was removed and radial margins are ≥ 2 mm for invasive cancer and DCIS.

5. pN0 (pN0 i+ is eligible for inclusion) by sentinel node biopsy and/or axillary dissection.

6. Absence of lymphovascular invasion and extensive intraductal component.

7. Have no additional BIRADS 3+ lesions not shown to be benign on pre-operative or surgical biopsy.

8. Participants must be allocated within 8 weeks after final breast surgery.

   • Oestrogen receptor and progesterone receptor status of invasive cancer will be assessed by immunohistochemistry on the diagnostic core biopsy specimen. The IHC results will be reported as percentage of nuclei stained and a score of intensity from negative, weak, intermediate or high staining

     • Where histopathology is unable to identify a 'bridge' of tumour tissue joining two or more apparent invasive cancer foci the following will be used to confirm unifocal disease:

       • All foci must be of the same histology
       • All foci must have the same hormone (ER and PR) and HER2 status. In relation to Allocation Criteria #3: the overall tumour size (including additional foci of DCIS) must remain ≤ 20 mm. The tumour size is defined as the longest distance between the outer most edges of all foci, the space between the two or more foci is included in the overall size: Size = ('Focus A + Focus B + 'the distance between A and B').

Allocation: Arm B - Standard Treatment

In addition to the above Inclusion Criteria, participants who fulfil one any of the following criteria will receive standard treatment:

1. Has moderate or marked parenchymal enhancement on pre-operative MRI.
2. Has a biopsy-proven malignant occult lesion (mOL) identified on MRI.
3. Suspicious lesion identified on CEM but not on MRI and confirmed on investigation to be a malignant lesion.
4. Surgical pathology does not meet the inclusion criteria.
5. Clinical team meeting determination that RT be recommended.
6. Participant chooses to have RT despite being eligible for RT omission.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Ipsilateral Invasive Recurrence Rate (IIRR) in all patients omitting RT at a median of 5 years follow up	Median of 5 years follow up	To determine the ipsilateral invasive recurrence rate (IIRR) in patients allocated to omit radiotherapy
Ipsilateral Invasive Recurrence Rate (IIRR) in low-risk patients omitting RT at a median of 5 years follow up	Median of 5 years follow up (when 300th low risk patient in Arm A reaches 5 years follow up)	To determine the ipsilateral invasive recurrence rate (IIRR) in patients with favourable clinico-pathological features on MRI and unequivocally unifocal breast cancer treated with wide local excision but no adjuvant radiotherapy

Secondary Outcome Measures

Name	Time	Method
PRO: Differences in Quality of Life Years (QALYs)	24 months post-surgery	Differences in QALYs between Arm A and Arm B measured by the EQ-5D-5L
Ipsilateral Invasive Recurrence Rate (IIRR) in all patients omitting RT at a median of 10 years follow up	Median of 10 years follow up	To determine the ipsilateral invasive recurrence rate (IIRR) in patients allocated to omit radiotherapy
IIRR in higher risk patients omitting RT and the total cohort omitting RT	Median of 5 years follow up	To determine the ipsilateral invasive recurrence rate (IIRR) in higher risk participants and the total cohort omitting RT.
IIR in the breast at 5 and 10 years in the entire cohort undergoing pre-operative MRI	Median of 5 and 10 years follow up	To determine the ipsilateral invasive recurrence rate (IIRR) in the breast at 5 and 10 years in the entire cohort undergoing preoperative MRI (Arms A + B).
Ipsilateral DCIS and invasive recurrence rate in all cohorts separately and combined	Median of 5 and 10 years follow up	Ipsilateral DCIS and invasive recurrence rate in all cohorts separately and combined
Regional recurrence rate in all participants	Median of 5 and 10 years follow up	To determine the regional recurrence rate in the entire cohort undergoing preoperative MRI (Arms A + B).
Overall survival rate	Median of 5 and 10 years follow up	To determine the overall survival rate in all groups separately and combined
PRO: HRQoL (functional and aesthetic outcomes)	24 months post-surgery	To determine the difference in HRQoL (functional and aesthetic outcomes) between Arm A and Arm B measured by the Breast Cancer Treatment Outcomes Scale (BCTOS). A higher score indicates greater morbidity.
PRO: HRQoL (fatigue, body image, financial toxicity)	24 months post-surgery	To determine the difference in HRQoL (fatigue, body image, financial toxicity) between Arm A and Arm B measured by the EORTC ILXX measure (custom measure for this protocol). A higher score indicates greater fatigue, poorer body image and greater financial toxicity.
PRO: Difference over time in FCR	From allocation to 3-, 6-, 12-, 24- and 60 months median follow up post-surgery	To determine the difference over time in FCR between Arm A and Arm B measured by the FCRI-SF. A higher score indicates a greater fear of recurrence.
PRO: Difference over time in HRQoL (functional and aesthetic outcomes)	From allocation to 6-, 12-, 24- and 60 months median follow up post-surgery	To determine the difference over time in HRQoL (functional and aesthetic outcomes), between Arm A and Arm B measured by the BCTOS. A higher BCTOS score indicates greater morbidity.
Ipsilateral DCIS recurrence rate in the entire cohort	Median of 5 and 10 years follow up.	To determine the ipsilateral DCIS recurrence rate in the entire cohort undergoing pre-operative MRI (Arms A + B).
Contralateral DCIS and invasive breast cancer in each arm separately, and combined	Median of 5 and 10 years follow up	To determine the contralateral DCIS and invasive breast cancer in Arm A, Arm B, and the total cohort (Arms A + B)
PRO: Fear of Cancer Recurrence	Median 24 months post-surgery	To determine the difference in Fear of cancer recurrence (FCR) between Arm A and Arm B measured by the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF). A higher score indicates a greater fear of recurrence.
IIRR in the breast at 5 and 10 years in the entire cohort undergoing pre-operative MRI and ineligible for RT omission	Median of 5 and 10 years follow up.	To determine the ipsilateral invasive recurrence rate (IIRR) in the breast at 5 and 10 years in the entire cohort undergoing preoperative MRI and found to be ineligible for RT omission after BCS (Arm B).
Distant recurrence rate in all participants	Median of 5 and 10 years follow up	To determine the distant recurrence rate in the entire cohort undergoing preoperative MRI (Arms A + B).
Breast cancer specific survival rate in all groups separately and combined	Median of 5 and 10 years follow up	To determine the breast cancer specific survival rate in all groups separately and combined
PRO: Difference over time in HRQoL (ffatigue, body image, financial toxicity)	From allocation to 6-, 12-, 24- and 60 months median follow up post-surgery	To determine the difference over time in HRQoL (fatigue, body image, financial toxicity), between Arm A and Arm B measured by the EORTC ILXX measure (custom measure for this protocol). A higher score indicates greater fatigue, poorer body image and greater financial toxicity.

Trial Locations

Locations (7)

Lake Macquarie Private Hospital; 🇦🇺 Gateshead, New South Wales, Australia

Mater Hospital, Sydney; 🇦🇺 North Sydney, New South Wales, Australia

Westmead Hospital; 🇦🇺 Westmead, New South Wales, Australia

Royal Adelaide Hospital; 🇦🇺 Adelaide, South Australia, Australia

Monash Cancer Centre (MMC Moorabbin); 🇦🇺 Clayton, Victoria, Australia

The Royal Melbourne Hospital; 🇦🇺 Melbourne, Victoria, Australia

The Chris O'Brien Lifehouse; 🇦🇺 Camperdown, New South Wales, Australia